Evidence map›Paper›PMID 39854359›Full record

SynthesisPloS one2025

A systematic review on malaria and Tuberculosis (TB) vaccine challenges in sub-Saharan African clinical trials.

Maonezi Abas Hamisi, Nur Ain Mohd Asri, Aini Syahida Mat Yassim, Rapeah Suppian

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maonezi Abas HamisiSchool of Science and Technical Education (CoSTE), Mbeya University of Science and Technology, Mbeya, Tanzania.ORCID 0009-0001-3810-9074
Nur Ain Mohd AsriSchool of Health Sciences, Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia.ORCID 0000-0003-4386-299X
Aini Syahida Mat YassimSchool of Health Sciences, Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia.
Rapeah SuppianSchool of Health Sciences, Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveFor more than a century, developing novel and effective vaccines against malaria and Tuberculosis (TB) infections has been a challenge. This review sought to investigate the reasons for the slow progress of malaria and TB vaccine candidates in sub-Saharan African clinical trials.

methodsThe systematic review protocol was registered on PROSPERO on July 26, 2023 (CRD42023445166). The research articles related to the immunogenicity, efficacy, or safety of malaria or TB vaccines that were published between January 1, 2012, and August 31, 2023, were searched on three databases: Web of Science (WoS), PubMed, and ClinicalTrials.gov.

resultsA total of 2342 articles were obtained, 50 of which met the inclusion criteria. 28 (56%) articles reported on malaria vaccine attributes, while 22 (44%) articles reported on TB vaccines. In both cases, the major challenges in sub-Saharan African clinical trials were immunogenicity and efficacy, rather than safety.

conclusionFactors such as population characteristics, pathogen genetic diversity, vaccine nature, strategy, and formulation were associated with slow progress of the malaria and TB vaccine candidates in sub-Saharan African clinical trials.

Indexed as

MalariaMalaria VaccinesTuberculosisTuberculosis VaccinesAfrica South of the SaharaClinical Trials as TopicHumansMalaria VaccinesTuberculosis Vaccines

Identifiers

PMID39854359
PMCPMC11760592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.